These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 24656524)

  • 21. The Impact of Sertraline Co-Administration on the Pharmacokinetics of Olanzapine: A Population Pharmacokinetic Analysis of the STOP-PD.
    Davies SJ; Mulsant BH; Flint AJ; Meyers BS; Rothschild AJ; Whyte EM; Kirshner MM; Sorisio D; Pollock BG; Bies RR
    Clin Pharmacokinet; 2015 Nov; 54(11):1161-8. PubMed ID: 25971243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses.
    Matthews JD; Bottonari KA; Polania LM; Mischoulon D; Dording CM; Irvin R; Fava M
    J Clin Psychiatry; 2002 Dec; 63(12):1164-70. PubMed ID: 12523877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression.
    Weissman J; Flint A; Meyers B; Ghosh S; Mulsant B; Rothschild A; Whyte E;
    Psychiatry Res; 2012 May; 197(3):221-6. PubMed ID: 22464991
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effective treatment of depressive disorder with psychotic symptoms by olanzapine combination therapy].
    Schmitt A; Braus DF
    Dtsch Med Wochenschr; 2000 Dec; 125(50):1526-9. PubMed ID: 11190762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Antipsychotic Medication on Brain Structure in Patients With Major Depressive Disorder and Psychotic Features: Neuroimaging Findings in the Context of a Randomized Placebo-Controlled Clinical Trial.
    Voineskos AN; Mulsant BH; Dickie EW; Neufeld NH; Rothschild AJ; Whyte EM; Meyers BS; Alexopoulos GS; Hoptman MJ; Lerch JP; Flint AJ
    JAMA Psychiatry; 2020 Jul; 77(7):674-683. PubMed ID: 32101271
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Old age depression and its treatment.
    Maierà E
    Psychiatr Danub; 2010 Nov; 22 Suppl 1():S124-5. PubMed ID: 21057419
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum monitoring of antipsychotic drug levels during concomitant administration of sertraline and antipsychotic medication.
    Pierson K; Addington D; Addington J; Patten S
    Can J Psychiatry; 2006 Oct; 51(11):715-8. PubMed ID: 17121171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
    Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
    Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features.
    Rothschild AJ; Williamson DJ; Tohen MF; Schatzberg A; Andersen SW; Van Campen LE; Sanger TM; Tollefson GD
    J Clin Psychopharmacol; 2004 Aug; 24(4):365-73. PubMed ID: 15232326
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genomic Investigation of Remission and Relapse of Psychotic Depression Treated with Sertraline plus Olanzapine: The STOP-PD II Study.
    Men X; Marshe V; Elsheikh SS; Alexopoulos GS; Marino P; Meyers BS; Mulsant BH; Rothschild AJ; Voineskos AN; Whyte EM; Kennedy JL; Flint AJ; Müller DJ
    Neuropsychobiology; 2023; 82(3):168-178. PubMed ID: 37015192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pilot of a randomised controlled trial of the selective serotonin reuptake inhibitor sertraline versus cognitive behavioural therapy for anxiety symptoms in people with generalised anxiety disorder who have failed to respond to low-intensity psychological treatments as defined by the National Institute for Health and Care Excellence guidelines.
    Buszewicz M; Cape J; Serfaty M; Shafran R; Kabir T; Tyrer P; Clarke CS; Nazareth I
    Health Technol Assess; 2017 Aug; 21(45):1-138. PubMed ID: 28853392
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
    Davidson JR; Meoni P; Haudiquet V; Cantillon M; Hackett D
    Depress Anxiety; 2002; 16(1):4-13. PubMed ID: 12203668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review.
    Gao K; Muzina D; Gajwani P; Calabrese JR
    J Clin Psychiatry; 2006 Sep; 67(9):1327-40. PubMed ID: 17017818
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study.
    Pollack MH; Simon NM; Zalta AK; Worthington JJ; Hoge EA; Mick E; Kinrys G; Oppenheimer J
    Biol Psychiatry; 2006 Feb; 59(3):211-5. PubMed ID: 16139813
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?
    Bandelow B; Baldwin DS; Dolberg OT; Andersen HF; Stein DJ
    J Clin Psychiatry; 2006 Sep; 67(9):1428-34. PubMed ID: 17017830
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A delusion assessment scale for psychotic major depression: Reliability, validity, and utility.
    Meyers BS; English J; Gabriele M; Peasley-Miklus C; Heo M; Flint AJ; Mulsant BH; Rothschild AJ;
    Biol Psychiatry; 2006 Dec; 60(12):1336-42. PubMed ID: 17046724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance.
    Shelton RC; Williamson DJ; Corya SA; Sanger TM; Van Campen LE; Case M; Briggs SD; Tollefson GD
    J Clin Psychiatry; 2005 Oct; 66(10):1289-97. PubMed ID: 16259543
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological treatment for psychotic depression.
    Wijkstra J; Lijmer J; Burger H; Cipriani A; Geddes J; Nolen WA
    Cochrane Database Syst Rev; 2015 Jul; (7):CD004044. PubMed ID: 26225902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological treatment for psychotic depression.
    Wijkstra J; Lijmer J; Burger H; Geddes J; Nolen WA
    Cochrane Database Syst Rev; 2013 Nov; (11):CD004044. PubMed ID: 24282034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.